Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Femasys Inc. (NASDAQ: FEMY) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As an emerging growth company and smaller reporting company, Femasys files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events affecting its business, capital structure and listing status.
Through these filings, investors can review detailed information about Femasys’ women’s health portfolio, including fertility products such as FemaSeed Intratubal Insemination and FemVue, and the FemBloc permanent birth control system. Current reports on Form 8-K have described milestones like FDA 510(k) clearance for the FemVue Controlled diagnostic device, IDE approval to advance the final phase of the FINALE pivotal trial for FemBloc, and international regulatory approvals for FemBloc in Europe and the UK. Other 8-K filings outline financing transactions, including senior secured convertible notes and associated warrants, as well as underwritten equity offerings.
Femasys’ filings also disclose its Nasdaq Capital Market listing under the symbol FEMY, notices related to continued listing requirements, and responses such as capital raises or bid-price compliance plans. Registration statements on Form S-1 and S-1/A provide further detail on offered securities, use of proceeds, risk factors and forward-looking statements related to the company’s fertility and permanent birth control strategy.
On Stock Titan, these FEMY filings are updated in real time from EDGAR and paired with AI-powered summaries that highlight key points in lengthy documents. Users can quickly locate 10-K and 10-Q reports, 8-K event disclosures, registration statements and other filings, and use AI-generated explanations to understand complex sections on clinical development, regulatory pathways, financing terms and Nasdaq compliance without reading every page.
Sipos Jeremy Alexander reported acquisition or exercise transactions in this Form 4 filing.
Femasys Inc. Chief Technology Officer Jeremy Alexander Sipos reported an award of 80,000 restricted stock units (RSUs) on February 2, 2026. Each RSU represents a contingent right to receive one share of Femasys (FEMY) common stock.
The 80,000 RSUs were granted at a price of $0 per unit and are held as direct beneficial ownership. The RSUs vest in four equal annual installments beginning on February 2, 2027, as long as Sipos remains employed by Femasys or one of its subsidiaries on each vesting date.
Femasys Inc. Chief Technology Officer Jeremy Alexander Sipos filed an initial statement of beneficial ownership of company securities. He directly holds 46,278 shares of Femasys common stock. In addition, he reports several employee stock options to buy common stock.
The options cover different grants with exercise prices ranging from $0.80 to $6.12 per share and expiration dates between June 30, 2027 and January 28, 2035. Some grants are fully vested, while others vest in equal installments over three or four years beginning on dates in 2023, 2024, and 2025.
Femasys Inc. reported that Nasdaq has granted the company a 180-day extension, until July 13, 2026, to regain compliance with Nasdaq’s minimum bid price requirement, which calls for its common stock to close at or above $1.00 per share for at least ten consecutive business days. The company had previously fallen out of compliance after its share price stayed below $1.00 for 30 consecutive business days. In support of its extension request, Femasys indicated it had more than $5 million in stockholders’ equity as of December 31, 2025 and informed Nasdaq of its intention to cure the deficiency, including potentially effecting a reverse stock split if needed. Femasys plans to continue monitoring its share price and consider available options to regain and maintain compliance with the listing standards.
Femasys Inc. is registering up to 68,416,943 shares of common stock for resale by selling stockholders. These shares consist of 19,281,254 shares issuable upon conversion of senior secured convertible notes and 49,135,689 shares issuable upon exercise of Series A-1, B-1 and C-1 common stock purchase warrants, all originally issued in a November 2025 private placement. The company will not receive proceeds from any resale of shares, but would receive cash if the warrants are exercised for cash.
Femasys is a women’s health biomedical innovator with FDA-cleared and internationally approved products for infertility treatment, fallopian tube assessment and cervical cancer diagnosis, and is advancing FemBloc non-surgical permanent birth control through a pivotal U.S. trial. Its common stock trades on Nasdaq under the symbol FEMY, with a last reported price of $0.5730 per share on December 30, 2025. The most recent audited financial statements include an auditor’s explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern due to recurring losses, negative operating cash flows and accumulated deficit.
Femasys Inc. reported that it has secured U.S. FDA clearance for its next-generation FemVue diagnostic device. This clearance means the updated FemVue system has met the agency’s requirements for marketing in the United States. The company disclosed the news through a press release, which is included as an exhibit to this report.
The FemVue device is described as a diagnostic product, and the clearance relates specifically to its next-generation version. While no financial figures or commercial details are provided here, obtaining FDA clearance is often an important regulatory milestone for a medical device company, as it allows the cleared product version to be offered to healthcare providers in the U.S.
Femasys Inc. (FEMY) disclosed that its Chief Executive Officer and director filed a Form 4 reporting the purchase of derivative securities on 11/07/2025 for an aggregate amount of
The reporting person acquired Senior Secured Convertible Notes due 2035, initially convertible at
Femasys Inc. (FEMY) reported that it announced financial results for the quarter ended September 30, 2025 and provided a corporate update.
The company furnished a related press release as Exhibit 99.1. The information furnished, including Exhibit 99.1, is not deemed filed under the Exchange Act.
Femasys Inc. (FEMY) disclosed that a director reported a transaction on 11/07/2025 involving senior secured convertible notes and three warrant series. The reported securities were purchased for an aggregate amount of $25,000.
The notes are convertible at an initial price of $0.73 per share into up to 34,122 shares of common stock, with shares potentially increasing as interest accrues and subject to Nasdaq-related limitations. The Series A-1, Series B-1, and Series C-1 warrants each cover 34,122 shares at initial exercise prices of $0.81, $0.92, and $1.10 per share, respectively. All instruments list an expiration of 11/07/2035 and include customary adjustment provisions for events such as stock splits or dividends.
Femasys Inc. (FEMY) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/07/2025, the officer acquired Senior Secured Convertible Notes and three warrant series (A-1, B-1, C-1) for an aggregate purchase amount of $25,000.
The notes are initially convertible at $0.73 per share and are linked to up to 34,122 underlying shares based on the original stated amount, with conversion subject to specified limitations. Each of the Series A-1, B-1, and C-1 warrants covers 34,122 underlying shares, became exercisable on 11/07/2025, and expires on 11/07/2035, with initial exercise prices of $0.81, $0.92, and $1.10 per share, respectively. Conversion and exercise terms are adjustable per the instruments’ provisions.
Femasys Inc. filed a Form 8-K reporting a business update and furnished a press release titled “Femasys Advances Global Growth with Second Partner Order for FemBloc in Europe.”
The disclosure indicates expanding commercial activity for FemBloc through a partner order in the European market. The press release is included as Exhibit 99.1 and is dated November 10, 2025.